You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

CLINICAL TRIALS PROFILE FOR ERTAPENEM SODIUM


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Ertapenem Sodium

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Indication NCT00090272 ↗ A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039) Completed Merck Sharp & Dohme Corp. Phase 3 2002-04-01 The objective of this study is to evaluate the safety and efficacy of a one time dose of an intravenous marketed drug being evaluated for a new indication as compared to a marketed drug already approved for the prevention of surgical site infection following colorectal surgery.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Ertapenem Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00090272 ↗ A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039) Completed Merck Sharp & Dohme Corp. Phase 3 2002-04-01 The objective of this study is to evaluate the safety and efficacy of a one time dose of an intravenous marketed drug being evaluated for a new indication as compared to a marketed drug already approved for the prevention of surgical site infection following colorectal surgery.
NCT00092170 ↗ An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038) Completed Merck Sharp & Dohme Corp. Phase 2 2002-03-01 The purpose of this study is to determine the effect of an approved medication for adults for an investigational use in pediatric patients 3 months to 17 years for the treatment of complicated intra-abdominal infections or acute pelvic infections.
NCT00379951 ↗ A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048) Completed Merck Sharp & Dohme Corp. Phase 3 2005-06-01 The purpose of this study is to evaluate the safety, tolerability and efficacy of ertapenem sodium as initial therapy for the treatment of complicated urinary tract infections, including pyelonephritis in indian adults.
NCT00379964 ↗ A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2005-06-01 The purpose of this study is to evaluate the safety, tolerability and efficacy of ertapenem sodium as initial therapy for the treatment of complicated urinary tract infections, including pyelonephritis in indian adults.
NCT00389987 ↗ Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037) Completed Merck Sharp & Dohme Corp. Phase 3 2001-09-01 This study is designed to compare the efficacy of ertapenem and piperacillin/tazobactam with respect to the clinical response in baseline microbiologically evaluable patients; and to evaluate the tolerability and safety of ertapenem compared to piperacillin/tazobactam.
NCT00397956 ↗ To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053) Completed Merck Sharp & Dohme Corp. Phase 3 2004-09-01 To collect clinical response data with the use of ertapenem in community acquired sepsis.
NCT00398099 ↗ To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052) Completed Merck Sharp & Dohme Corp. Phase 3 2005-07-01 To collect clinical response data with the use of ertapenem in approved indications.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ertapenem Sodium

Condition Name

Condition Name for Ertapenem Sodium
Intervention Trials
Urinary Tract Infection 3
Infection 2
Infection; Diabetic Foot 1
Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ertapenem Sodium
Intervention Trials
Infections 7
Infection 7
Communicable Diseases 7
Urinary Tract Infections 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ertapenem Sodium

Trials by Country

Trials by Country for Ertapenem Sodium
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ertapenem Sodium
Location Trials
Texas 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ertapenem Sodium

Clinical Trial Phase

Clinical Trial Phase for Ertapenem Sodium
Clinical Trial Phase Trials
Phase 4 1
Phase 3 9
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ertapenem Sodium
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ertapenem Sodium

Sponsor Name

Sponsor Name for Ertapenem Sodium
Sponsor Trials
Merck Sharp & Dohme Corp. 11
M.D. Anderson Cancer Center 1
Albany College of Pharmacy and Health Sciences 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ertapenem Sodium
Sponsor Trials
Industry 11
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.